Skip to main content
medRxiv
  • Home
  • About
  • Submit
  • ALERTS / RSS
Advanced Search

The Breadth of the Neutralizing Antibody Response to Original SARS-CoV-2 Infection is Linked to the Presence of Long COVID Symptoms

Amanda M. Buck, Amelia N. Deitchman, Saki Takahashi, Scott Lu, Sarah A. Goldberg, Rebecca Hoh, Meghann C. Williams, Marian Kerbleski, Tyler-Marie Deveau, Sadie E. Munter, James Lombardo, Terri Wrin, Christos J. Petropoulos, Matthew S. Durstenfeld, Priscilla Y. Hsue, J. Daniel Kelly, Bryan Greenhouse, Jeffrey N. Martin, Steven G. Deeks, Michael J. Peluso, Timothy J. Henrich
doi: https://doi.org/10.1101/2023.03.30.23287923
Amanda M. Buck
1Division of Experimental Medicine, University of California San Francisco, San Francisco, CA, United States
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Amelia N. Deitchman
6Department of Clinical Pharmacy, University of California San Francisco, San Francisco, CA, United States
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Saki Takahashi
2Division of HIV, ID and Global Medicine, University of California San Francisco, San Francisco, CA, United States
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Scott Lu
3Department of Epidemiology and Biostatistics, University of California San Francisco, San Francisco, CA, United States
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Sarah A. Goldberg
3Department of Epidemiology and Biostatistics, University of California San Francisco, San Francisco, CA, United States
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Rebecca Hoh
2Division of HIV, ID and Global Medicine, University of California San Francisco, San Francisco, CA, United States
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Meghann C. Williams
2Division of HIV, ID and Global Medicine, University of California San Francisco, San Francisco, CA, United States
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Marian Kerbleski
2Division of HIV, ID and Global Medicine, University of California San Francisco, San Francisco, CA, United States
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Tyler-Marie Deveau
1Division of Experimental Medicine, University of California San Francisco, San Francisco, CA, United States
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Sadie E. Munter
1Division of Experimental Medicine, University of California San Francisco, San Francisco, CA, United States
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
James Lombardo
2Division of HIV, ID and Global Medicine, University of California San Francisco, San Francisco, CA, United States
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Terri Wrin
4Monogram Biosciences, South San Francisco, CA, United States
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Christos J. Petropoulos
4Monogram Biosciences, South San Francisco, CA, United States
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Matthew S. Durstenfeld
5Division of Cardiology, University of California San Francisco, San Francisco, CA, United States
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Priscilla Y. Hsue
5Division of Cardiology, University of California San Francisco, San Francisco, CA, United States
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
J. Daniel Kelly
3Department of Epidemiology and Biostatistics, University of California San Francisco, San Francisco, CA, United States
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Bryan Greenhouse
2Division of HIV, ID and Global Medicine, University of California San Francisco, San Francisco, CA, United States
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Jeffrey N. Martin
3Department of Epidemiology and Biostatistics, University of California San Francisco, San Francisco, CA, United States
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Steven G. Deeks
2Division of HIV, ID and Global Medicine, University of California San Francisco, San Francisco, CA, United States
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Michael J. Peluso
2Division of HIV, ID and Global Medicine, University of California San Francisco, San Francisco, CA, United States
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • For correspondence: michael.peluso{at}ucsf.edu timothy.henrich{at}ucsf.edu
Timothy J. Henrich
1Division of Experimental Medicine, University of California San Francisco, San Francisco, CA, United States
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • For correspondence: michael.peluso{at}ucsf.edu timothy.henrich{at}ucsf.edu
  • Abstract
  • Full Text
  • Info/History
  • Metrics
  • Data/Code
  • Preview PDF
Loading

ABSTRACT

Background The associations between longitudinal dynamics and the breadth of SARS-CoV-2 neutralizing antibody response with various Long COVID (LC) phenotypes prior to vaccination are not known. The capacity of antibodies to cross neutralize a variety of viral variants may be associated with ongoing pathology and persistent symptoms.

Methods We measured longitudinal neutralizing and cross-neutralizing antibody responses to pre- and post-SARS-CoV-2 Omicron variants in participants infected during the early waves of the COVID-19 pandemic, prior to wide-spread rollout of SARS-CoV-2 vaccines. Cross sectional regression models adjusted for various clinical covariates and longitudinal mixed effects models were used to determine the impact of the breadth and rate of decay of neutralizing responses on the development of Long COVID symptoms in general, as well as LC phenotypes.

Results We identified several novel relationships between SARS-CoV-2 antibody neutralization and the presence of LC symptoms. Specifically, we show that, although neutralizing antibody responses to the original, infecting strain of SARS-CoV-2 were not associated with LC in cross-sectional analyses, cross-neutralization ID50 levels to the Omicron BA.5 variant approximately 4 months following acute infection was independently and significantly associated with greater odds of LC and with persistent gastrointestinal and neurological symptoms. Longitudinal modeling demonstrated significant associations in the overall levels and rates of decay of neutralization capacity with LC phenotypes. A higher proportion of participants had antibodies capable of neutralizing Omicron BA.5 compared with BA.1 or XBB.1.5 variants.

Conclusions Our findings suggest that relationships between various immune responses and LC are likely complex but may involve the breadth of antibody neutralization responses.

Summary SARS-CoV-2-specific antibody neutralization of Omicron BA.5 variant approximately 4 months following acute infection with wild-type virus prior to vaccination was independently and significantly associated with greater odds of distinct Long COVID phenotypes.

Competing Interest Statement

MJP reports consulting fees for Gilead Sciences and AstraZeneca, outside the submitted work. TJH receives grant support from Merck and Co. and has consulted for Roche and Regeneron.

Funding Statement

This work was supported by the NIH/National Institute of Allergy and Infectious Diseases 3R01AI141003-03S1 (TJH), K23A137522 (MJP), and K23AI162249 (AND).

Author Declarations

I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.

Yes

The details of the IRB/oversight body that provided approval or exemption for the research described are given below:

IRB of the University of California San Francisco gave ethical approval for this work.

I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.

Yes

I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).

Yes

I have followed all appropriate research reporting guidelines, such as any relevant EQUATOR Network research reporting checklist(s) and other pertinent material, if applicable.

Yes

Data Availability

All data produced in the present study are available upon reasonable request to the authors.

Copyright 
The copyright holder for this preprint is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. It is made available under a CC-BY 4.0 International license.
Back to top
PreviousNext
Posted March 31, 2023.
Download PDF
Data/Code
Email

Thank you for your interest in spreading the word about medRxiv.

NOTE: Your email address is requested solely to identify you as the sender of this article.

Enter multiple addresses on separate lines or separate them with commas.
The Breadth of the Neutralizing Antibody Response to Original SARS-CoV-2 Infection is Linked to the Presence of Long COVID Symptoms
(Your Name) has forwarded a page to you from medRxiv
(Your Name) thought you would like to see this page from the medRxiv website.
CAPTCHA
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.
Share
The Breadth of the Neutralizing Antibody Response to Original SARS-CoV-2 Infection is Linked to the Presence of Long COVID Symptoms
Amanda M. Buck, Amelia N. Deitchman, Saki Takahashi, Scott Lu, Sarah A. Goldberg, Rebecca Hoh, Meghann C. Williams, Marian Kerbleski, Tyler-Marie Deveau, Sadie E. Munter, James Lombardo, Terri Wrin, Christos J. Petropoulos, Matthew S. Durstenfeld, Priscilla Y. Hsue, J. Daniel Kelly, Bryan Greenhouse, Jeffrey N. Martin, Steven G. Deeks, Michael J. Peluso, Timothy J. Henrich
medRxiv 2023.03.30.23287923; doi: https://doi.org/10.1101/2023.03.30.23287923
Twitter logo Facebook logo LinkedIn logo Mendeley logo
Citation Tools
The Breadth of the Neutralizing Antibody Response to Original SARS-CoV-2 Infection is Linked to the Presence of Long COVID Symptoms
Amanda M. Buck, Amelia N. Deitchman, Saki Takahashi, Scott Lu, Sarah A. Goldberg, Rebecca Hoh, Meghann C. Williams, Marian Kerbleski, Tyler-Marie Deveau, Sadie E. Munter, James Lombardo, Terri Wrin, Christos J. Petropoulos, Matthew S. Durstenfeld, Priscilla Y. Hsue, J. Daniel Kelly, Bryan Greenhouse, Jeffrey N. Martin, Steven G. Deeks, Michael J. Peluso, Timothy J. Henrich
medRxiv 2023.03.30.23287923; doi: https://doi.org/10.1101/2023.03.30.23287923

Citation Manager Formats

  • BibTeX
  • Bookends
  • EasyBib
  • EndNote (tagged)
  • EndNote 8 (xml)
  • Medlars
  • Mendeley
  • Papers
  • RefWorks Tagged
  • Ref Manager
  • RIS
  • Zotero
  • Tweet Widget
  • Facebook Like
  • Google Plus One

Subject Area

  • Infectious Diseases (except HIV/AIDS)
Subject Areas
All Articles
  • Addiction Medicine (430)
  • Allergy and Immunology (756)
  • Anesthesia (221)
  • Cardiovascular Medicine (3294)
  • Dentistry and Oral Medicine (364)
  • Dermatology (279)
  • Emergency Medicine (479)
  • Endocrinology (including Diabetes Mellitus and Metabolic Disease) (1171)
  • Epidemiology (13376)
  • Forensic Medicine (19)
  • Gastroenterology (899)
  • Genetic and Genomic Medicine (5153)
  • Geriatric Medicine (482)
  • Health Economics (783)
  • Health Informatics (3268)
  • Health Policy (1140)
  • Health Systems and Quality Improvement (1190)
  • Hematology (431)
  • HIV/AIDS (1017)
  • Infectious Diseases (except HIV/AIDS) (14629)
  • Intensive Care and Critical Care Medicine (913)
  • Medical Education (477)
  • Medical Ethics (127)
  • Nephrology (523)
  • Neurology (4925)
  • Nursing (262)
  • Nutrition (730)
  • Obstetrics and Gynecology (883)
  • Occupational and Environmental Health (795)
  • Oncology (2524)
  • Ophthalmology (724)
  • Orthopedics (281)
  • Otolaryngology (347)
  • Pain Medicine (323)
  • Palliative Medicine (90)
  • Pathology (543)
  • Pediatrics (1302)
  • Pharmacology and Therapeutics (550)
  • Primary Care Research (557)
  • Psychiatry and Clinical Psychology (4212)
  • Public and Global Health (7504)
  • Radiology and Imaging (1706)
  • Rehabilitation Medicine and Physical Therapy (1013)
  • Respiratory Medicine (980)
  • Rheumatology (480)
  • Sexual and Reproductive Health (497)
  • Sports Medicine (424)
  • Surgery (548)
  • Toxicology (72)
  • Transplantation (236)
  • Urology (205)